Stereotaxis

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top-line but beat on the bottom-line: revenue of $7.67M was 8.14% below the $8.35M expected, primarily due to a significant decrease in system sales volume. However, gross margin expanded to 58.49% (vs. 58.28% expected) due to favorable product mix, and EPS GAAP of -$0.05 beat the consensus of -$0.06. The quarter was marked by the strategic acquisition of Robocath and regulatory clearances for the Synchrony and MAGiC products, despite ongoing pressure from the Johnson & Johnson catheter transition.